Senseonics Holdings (SENS) AI Stock Analysis

• Market Cap: $379.03M
• Dividend Yield: N/A
• Average Volume (3M): 6.19M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.76
• Revenue Growth: 1.64%
• EPS Growth: 16.02%
• Country: US
• Employees: 117
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Devices
• EPS (TTM): -0.02
• Shares Outstanding: 754,291,100
• 10 Day Avg. Volume: 8,703,106
• 30 Day Avg. Volume: 6,194,476
• PEG Ratio: -0.32
• Price to Book (P/B): 10.26
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.46
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: 4.11
• Enterprise Value/Gross Profit: 223.25
• Enterprise Value/Ebitda: -1.36
• 1Y Price Target: $1.55
• Price Target Upside: 210.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 48 Neutral
• Price Target: $0.50 ▲(0.00%Upside)

Senseonics Holdings' overall stock score is primarily impacted by its financial performance and technical analysis. The company's significant operational losses, high debt levels, and negative trend indicators weigh heavily on the score. However, a positive outlook from the earnings call, with strong revenue growth and strategic initiatives, provides some optimism for future performance.

Positive Factors

Partnerships

The partnership with Ascensia Diabetes Care now markets E365 to more than 2,400 annual prescribers, with the majority being new prescribers.

Patient Base Growth

The approval of the Eversense 365 continuous glucose monitor system drove a 56% increase in patient base in 2024 over 2023 to approximately 6,000 global patients.

Product Approval

Eversense 365 is the first and only 365-day integrated continuous glucose monitoring (CGM) system approved by the FDA for people with Type 1 and Type 2 diabetes aged 18 years and older.

Negative Factors

Financial Concerns

SENS shares are considered expensive as they trade at a high multiple of projected sales and the company is burning cash, increasing the risk of dilution.

Market Competition

There is skepticism about SENS's ability to gain traction in the CGM market against established competitors, despite the 365-day indication.

Senseonics Holdings Business Overview & Revenue Model

Company Description

Senseonics Holdings, Inc. is a medical technology company focused on the design, development, and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company's primary product is the Eversense CGM system, which provides continuous glucose readings, alerts, and data to help manage diabetes effectively. The Eversense system is unique in its use of a fully implantable sensor that can last for months, unlike traditional CGM systems that require frequent sensor replacements.

How the Company Makes Money

Senseonics Holdings generates revenue primarily through the sale of its Eversense CGM systems and related supplies. The company's revenue model is based on direct sales to healthcare providers and distribution partnerships that facilitate the delivery of its products to end-users. Significant partnerships, such as those with medical device distributors and healthcare providers, play a crucial role in expanding the market reach and accessibility of the Eversense system. Additionally, Senseonics may earn revenue from licensing agreements and collaborations with other companies in the diabetes care industry, although these represent a smaller portion of their overall revenue.

Senseonics Holdings Financial Statement Overview

Summary

Senseonics Holdings is facing financial challenges typical for a growing company in the medical devices industry. While there's some revenue growth and improved equity position, significant operational losses are impacting profitability, and high debt levels pose risks. Negative cash flows highlight the need for strategic adjustments to improve financial health.

Income Statement

Senseonics Holdings has shown some revenue growth, with a 5.76% increase in TTM revenue compared to the previous year. However, the company is facing significant profitability challenges, as evidenced by negative EBIT and EBITDA margins. The TTM net profit margin remains deeply negative at -312.34%, reflecting ongoing struggles with high operational losses.

Balance Sheet

The company's balance sheet shows a concerning debt-to-equity ratio due to negative equity in prior years, though it has improved to a positive equity position recently. The TTM equity ratio is 40.35%, indicating a moderate level of equity relative to total assets. However, the high total debt relative to equity remains a potential risk factor for financial stability.

Cash Flow

While the operating cash flow is negative, indicating cash outflows from core operations, the free cash flow has improved slightly over the past year. The TTM operating cash flow to net income ratio is less concerning given the net income losses, but cash flow remains a key area for improvement to ensure sustainability.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	23.68M	22.39M	16.39M	13.68M	4.95M	21.30M
Gross Profit	1.70M	3.09M	2.73M	-811.00K	-17.37M	-19.45M
EBITDA	-65.69M	-48.01M	161.81M	-284.51M	-157.86M	-99.41M
Net Income	-74.00M	-60.39M	142.12M	-302.47M	-175.17M	-115.55M
Balance Sheet
Total Assets	87.21M	138.22M	177.67M	198.93M	35.92M	132.60M
Cash, Cash Equivalents and Short-Term Investments	39.31M	109.46M	144.01M	129.91M	18.00M	95.94M
Total Debt	40.63M	47.78M	74.65M	63.30M	62.70M	119.22M
Total Liabilities	52.01M	64.77M	180.25M	384.46M	180.00M	141.45M
Stockholders Equity	35.20M	73.45M	-2.58M	-185.53M	-144.08M	-8.85M
Cash Flow
Free Cash Flow	-58.64M	-70.51M	-66.62M	-56.29M	-67.60M	-137.09M
Operating Cash Flow	-56.28M	-70.16M	-66.31M	-56.08M	-67.42M	-136.05M
Investing Cash Flow	-17.87M	89.71M	26.88M	-148.75M	-181.00K	-1.04M
Financing Cash Flow	22.91M	20.37M	41.76M	220.08M	-10.13M	96.24M

Senseonics Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SENS, the sentiment is Negative. The current price of 0.5 is below the 20-day moving average (MA) of 0.51, below the 50-day MA of 0.57, and below the 200-day MA of 0.57, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 42.48 is Neutral, neither overbought nor oversold. The STOCH value of 33.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SENS.

Senseonics Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DXCM	78 Outperform	$32.52B	62.26	23.72%	―	9.11%	-17.87%
LIVN	62 Neutral	$2.52B	30.62	-19.69%	―	7.97%	-592.40%
OM	55 Neutral	$369.96M	―	-86.53%	―	-7.84%	42.34%
TNDM	50 Neutral	$1.12B	―	-92.31%	―	27.65%	-28.22%
SENS	48 Neutral	$379.03M	―	-161.19%	―	1.64%	16.02%
NNOX	48 Neutral	$339.21M	―	-30.11%	―	15.32%	15.73%
Sector *	46 Neutral	C$194.28M	-4.22	-8.60%	2.64%	13.54%	-1.44%

Senseonics Holdings Corporate Events

Senseonics Holdings Approves Director Elections and Proposals

At the Annual Meeting on May 21, 2025, Senseonics Holdings‘ stockholders voted on three proposals. The election of four directors was approved, with all nominees elected to serve until the 2028 annual meeting. Additionally, the stockholders approved the compensation for the company’s named executive officers and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (SENS) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.

Senseonics Holdings Announces Major Stock Offering Agreement

On May 15, 2025, Senseonics Holdings, Inc. announced an underwriting agreement with TD Securities and Barclays Capital to issue and sell 100,000,000 shares of common stock at $0.50 per share, with an option for underwriters to purchase an additional 15,000,000 shares. The expected net proceeds of approximately $45.4 million, or $52.45 million if the option is exercised, will fund the launch of Eversense 365, development of pipeline products, and general corporate purposes. The offering is part of a shelf registration and includes a concurrent private placement with Abbott Laboratories for up to $25 million. The closing is expected on May 19, 2025, subject to customary conditions.

The most recent analyst rating on (SENS) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.

Senseonics Holdings Enters Agreement with Abbott Laboratories

On May 15, 2025, Senseonics Holdings entered into a securities purchase agreement with Abbott Laboratories to sell up to $25 million of its common stock in a private placement, contingent upon the closing of a proposed public offering. This strategic move includes granting Abbott certain negotiation rights for potential future transactions, which could impact the company’s operational and market strategies. The agreement reflects Senseonics’ efforts to strengthen its financial position and explore strategic opportunities, potentially affecting stakeholders and the company’s industry positioning.

The most recent analyst rating on (SENS) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.